Analysts Are Bullish On Insulet’s Omnipod 5 For Managing Type 1 Diabetes
A trial of Insulet’s Omnipod 5 trial in children and adults showed improvements in time and range and hemoglobin A1c after three months of use compared to standard therapy.
You may also be interested in...
The annual J.P. Morgan Healthcare Conference includes presentations from many major medtech companies outlining their growth strategies and expectations for 2021. Here are some of the highlights from the second day of the meeting.
Vicarious Surgical, whose medical robot received US FDA breakthrough designation, announced it will merge with D8 Holdings Corp. The deal is expected to garner up to $460m.
In this week’s podcast, Medtech Insight managing editor Marion Webb discusses plans by the Mayo Clinic and Veterans Health Administration to position themselves as medical device makers of 3D-printing technologies. UK-based reporter Barnaby Pickering gives an overview of global market for arthroscopy and sports medicine products.